New assay to detect genetic abnormalities in sarcomas outperforms conventional techniques

August 20, 2018, Elsevier
Dermatofibrosarcoma protuberans, a rare tumor harboring a COL1A1-PDGFB translocation. A: Hematoxylin and eosin staining shows classic morphology with storiform-arranged spindle tumor cells. B: Although FISH using commercial probes revealed no rearrangement, specifically designed FISH probes reveal colocalization of red (PDGFB) and green (COL1A1) signals, indicating a COL1A1-PDGFB fusion. C: Archer analysis software version 5.0 reveals both fusion partners (COL1A1, exon 10; and PDGFB, exon 2). D: Sanger sequencing of PCR product confirms a COL1A1-PDGFB fusion. Original magnification: x20 (A); x140 (B). Credit: The Journal of Molecular Diagnostics

Sarcomas are rare tumors that are often misdiagnosed. Specific recurrent chromosomal rearrangements, known as translocations, can serve as essential diagnostic markers and are found in about 20 percent of sarcomas. Identification of these translocations helps establish a correct diagnosis and guides treatment. A report in the Journal of Molecular Diagnostics describes a new assay, anchored multiplex PCR (AMP)-based targeted next-generation-sequencing (NGS), with superior diagnostic utility compared to conventional techniques. This includes the ability to analyze numerous target genes simultaneously and identify new fusion partners. In four cases, the assay diagnosed sarcoma in samples deemed falsely negative by conventional tests.

"Sarcomas are rare cancers of bone, fat, or muscle that are difficult to diagnose and are often misdiagnosed. More than 50 subtypes exist. Until now, for each sarcoma subtype and each translocation, a single assay test had to be performed detecting the presence of one single, specific gene fusion. Now, in contrast to conventional methods, 26 different genes can be analyzed for their involvement in a translocation in one single assay," explained Judith V.M.G. Bovée, MD, Ph.D., of the Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands.

To validate the utility of this novel test, investigators analyzed 81 samples using the new AMP technique, for NGS using the Archer FusionPlex Sarcoma Kit. They then compared the results to those of more conventional methods, such as fluorescence in situ hybridization (FISH) and reverse-transcriptase PCR.

The goal of these techniques is to identify specific genetic abnormalities in which regions of genetic material are rearranged (translocated), which can help in diagnosis. "Both FISH and reverse transcription-PCR are accompanied by challenges in routine application. Due to these limitations, the need for novel methods for fusion detection has grown significantly as more and more recurrent translocations are revealed with the advance of NGS," noted co-author Suk Wai Lam, MD, of the Department of Pathology of Leiden University Medical Center, Leiden, The Netherlands.

Of the 81 samples analyzed by the new technique, 70 samples were successfully analyzed. Fusions were found in 48 of those, whereas 22 were fusion-negative. In 90 percent of the cases the results using the new assay agreed with the results of conventional testing.

In four cases, conventional methods missed the translocation (three with FISH and one with reverse transcription-PCR). This problem may occur more frequently in Ewing sarcoma, in which the primer used by reverse transcription-PCR is focused on the most common fusion type and may miss less common alternatives. In another case of Ewing , the presence of complex rearrangements went beyond the capabilities of FISH, whereas NGS produced definitive results.

In a case of dermatofibrosarcoma protuberans, the more detailed findings provided by the new assay yielded crucial information that impacted patient management. The assay confirmed the presence of the rare COL1A1-PDGFB translocation, which opened the way for the patient to receive targeted therapy with imatinib.

The new assay also offers other distinct advantages. Its high sensitivity allows it to pick up the presence of a in small samples, and it can be used for analysis of formalin-fixed, paraffin-embedded material as well as fresh frozen tissue. Nevertheless, the study showed a failure rate of 14 percent for AMP-based targeted NGS. "None of the molecular assays used in the current study was able to provide a hundred percent of certainty with respect to false-positive and false-negative results," stated Dr. Lam. "However, we believe this novel test will assist the pathologist in establishing the in the complex world of sarcomas."

Explore further: Sensitive new assay finds abnormalities in tumor cells that other techniques may miss

More information: Suk Wai Lam et al, Molecular Analysis of Gene Fusions in Bone and Soft Tissue Tumors by Anchored Multiplex PCR–Based Targeted Next-Generation Sequencing, The Journal of Molecular Diagnostics (2018). DOI: 10.1016/j.jmoldx.2018.05.007

Related Stories

Sensitive new assay finds abnormalities in tumor cells that other techniques may miss

June 18, 2018
RNA-Seq is a new next-generation assay that can detect gene fusions in solid tumor cells with high accuracy and excellent reproducibility. According to a new report in The Journal of Molecular Diagnostics, the assay detected ...

Is your lung cancer really ROS1-negative? Study shows it may be worth testing again

August 8, 2018
Drugs like crizotinib are used to treat patients with ROS1-positive lung cancer. But which patients are ROS1-positive? A University of Colorado Cancer Center study published in the Journal of Thoracic Oncology shows that ...

Combined FISH and IHC identifies patients with rare ALK Fusions that respond to crizotinib

September 12, 2016
The combined use of fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) identified non-small cell lung cancer (NSCLC) patients with rare or novel anaplastic lymphoma kinase (ALK) gene rearrangements, ...

Team defines the mechanisms of action of key genetic abnormality in Ewing sarcoma

August 2, 2018
A Massachusetts General Hospital (MGH) research team has used epigenome editing tools to investigate how the genetic abnormality that drives Ewing sarcoma—the second most common bone cancer in children and young adults—unleashes ...

Cancer researchers validate a clinical test for fusion genes

August 14, 2017
An assay that identifies a peculiar but important abnormality in cancer cells has been developed and validated by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and ...

FDA-approved ALK IHC CDx superior to another IHC assay for patient selection

February 22, 2016
The U.S. Food and Drug Administration (FDA) approved VENTANA anti-ALK(D5F3)CDx performed more accurately than another commonly used immunohistochemistry (IHC) assay, based on the use of the 5A4 clone, for the selection of ...

Recommended for you

Researchers discover important connection between cells in the liver

November 15, 2018
University of Minnesota Medical School researchers have made a discovery which could lead to a new way of thinking about how disease pathogenesis in the liver is regulated, which is important for understanding the condition ...

Gut hormone and brown fat interact to tell the brain it's time to stop eating

November 15, 2018
Researchers from Germany and Finland have shown that so-called "brown fat" interacts with the gut hormone secretin in mice to relay nutritional signals about fullness to the brain during a meal. The study, appearing November ...

Brain, muscle cells found lurking in kidney organoids grown in lab

November 15, 2018
Scientists hoping to develop better treatments for kidney disease have turned their attention to growing clusters of kidney cells in the lab. One day, so-called organoids—grown from human stem cells—may help repair damaged ...

How the Tasmanian devil inspired researchers to create 'safe cell' therapies

November 15, 2018
A contagious facial cancer that has ravaged Tasmanian devils in southern Australia isn't the first place one would look to find the key to advancing cell therapies in humans.

Precision neuroengineering enables reproduction of complex brain-like functions in vitro

November 14, 2018
One of the most important and surprising traits of the brain is its ability to dynamically reconfigure the connections to process and respond properly to stimuli. Researchers from Tohoku University (Sendai, Japan) and the ...

Gene mutation found to cause macrocephaly and intellectual deficits

November 13, 2018
The absence of one copy of a single gene in the brain causes a rare, as-yet-unnamed neurological disorder, according to new research that builds on decades of work by a University at Buffalo biochemist and his colleagues.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.